Search

Your search keyword '"Combredet, Chantal"' showing total 3 results
Start Over Author "Combredet, Chantal" Publisher hal ccsd
3 results on '"Combredet, Chantal"'

1. Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells

Author

Grard, Marion, Idjellidaine, Mohamed, Arbabian, Atousa, Chatelain, Camille, Berland, Laurine, Combredet, Chantal, Dutoit, Soizic, Deshayes, Sophie, Dehame, Virginie, Labarrière, Nathalie, Fradin, Delphine, Boisgerault, Nicolas, Blanquart, Christophe, Tangy, Frédéric, Fonteneau, Jean-François, LabEX IGO Immunothérapie Grand Ouest, Nantes Université (Nantes Univ), Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers (CRCI2NA ), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Laboratoire d’innovation : vaccins – Innovation lab : vaccines, Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Immunology and New Concepts in ImmunoTherapy (INCIT), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), This work was supported by 'La Ligue Régionale Grand Ouest contre le Cancer' (CD16, CD22, CD44, CD49, CD72, CD79 and CD85), 'l’association ARSMESO44', 'la Fondation ARC (PJA 20191209661)', 'l’Agence Nationale pour la Recherche (ANR-16-CE18-0016)', and 'LabEX IGO' program supported by the National Research Agency via the investment of the future program ANR-11-LABX-0016–01'., ANR-16-CE18-0016,OncoMeVax,Un virus de la rougeole modifié pour traiter le cancer(2016), and ANR-11-LABX-0016,IGO,Immunothérapies Grand Ouest(2011)

Subjects
[SDV]Life Sciences [q-bio], [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology
Abstract

International audience; Antitumor virotherapy stimulates the antitumor immune response during tumor cell lysis induced by oncolytic viruses (OVs). OV can be modified to express additional transgenes that enhance their therapeutic potential. In this study, we armed the spontaneously oncolytic Schwarz strain of measles viruses (MVs) with the gene encoding the cancer/testis antigen NY-ESO-1 to obtain MVny. We compared MV and MVny oncolytic activity and ability to induce NY-ESO-1 expression in six human melanoma cell lines. After MVny infection, we measured the capacity of melanoma cells to present NY-ESO-1 peptides to CD4 + and CD8 + T cell clones specific for this antigen. We assessed the ability of MVny to induce NY-ESO-1 expression and presentation in monocyte-derived dendritic cells (DCs). Our results show that MVny and MV oncolytic activity are similar with a faster cell lysis induced by MVny. We also observed that melanoma cell lines and DC expressed the NY-ESO-1 protein after MVny infection. In addition, MVny-infected melanoma cells and DCs were able to stimulate NY-ESO-1-specific CD4 + and CD8 + T cells. Finally, MVny was able to induce DC maturation. Altogether, these results show that MVny could be an interesting candidate to stimulate NY-ESO-1-specific T cells in melanoma patients with NY-ESO-1-expressing tumor cells.

Published
2023
Full Text
View/download PDF

2. Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells

Author

Achard, Carole, Guillerme, Jean-Baptiste, Bruni, Daniela, Boisgerault, Nicolas, Combredet, Chantal, Tangy, Frédéric, Jouvenet, Nolwenn, Grégoire, Marc, Fonteneau, Jean-François, Bernardo, Elizabeth, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Génomique virale et vaccination, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), This work was supported by 'La Ligue Régionale Grand Ouest contre le Cancer' (CSIRGO: CD16, CD22, CD44, CD49, CD72, CD79 and CD85), 'La Ligue Nationale contre le Cancer, l'association ARSMESO44, 'La Fondation du Souffle et le Fonds de Dotation Recherche en Santé Respiratoire, 'La fondation ARC, 'la Fondation pour la Recherche Médicale (FRM), 'Agence Nationale pour la Recherche (ANR-12-JSV3–003–01) and Ville de Paris EMERGENCES Program., and Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV.CAN] Life Sciences [q-bio]/Cancer, Measles virus, plasmacytoid dendritic cells, myeloid dendritic cells, type I interferon, chemical and pharmacologic phenomena, hemic and immune systems, TRAIL, [SDV.CAN]Life Sciences [q-bio]/Cancer, Original Research, oncolytic virus
Abstract

International audience; Attenuated measles virus (MV) is currently being evaluated in clinical trials as an oncolytic therapeutic agent. Originally used for its lytic activity against tumor cells, it is now admitted that the effectiveness of MV also lies in its ability to initiate antitumor immune responses through the activation of dendritic cells (DCs). In this study, we investigated the capacity of oncolytic MV to convert human blood myeloid CD1cC DCs and plasmacytoid DCs (pDCs) into cytotoxic effectors. We found that MV induces the expression of the cytotoxic protein TNF-related apoptosis-inducing ligand (TRAIL) on the surface of DCs. We demonstrate that the secretion of interferon-a (IFN-a) by DCs in response to MV is responsible for this TRAIL expression. Several types of PRRs (pattern recognition receptors) have been implicated in MV genome recognition, including RLRs (RIG-I-like receptors) and TLRs (Toll-like receptors). We showed that CD1cC DCs secrete modest amounts of IFN-a and express TRAIL in an RLR-dependent manner upon exposure to MV. In pDCs, MV is recognized by RLRs and also by TLR7, leading to the secretion of high amounts of IFN-a and TRAIL expression. Finally, we showed that MV-stimulated DCs induce TRAILmediated cell death of Jurkat cells, confirming their acquisition of cytotoxic functions. Our results demonstrate that MV can activate cytotoxic myeloid CD1cC DCs and pDCs, which may participate to the antitumor immune response.

Published
2016
Full Text
View/download PDF

3. A recombinant measles virus vaccine strongly reduces SHIV viremia and virus reservoir establishment in macaques

Author

Nathalie Dereuddre-Bosquet, Géraldine Schlecht-Louf, Patrycja Nzounza, Roger Le Grand, Valérie Najburg, Grégoire Martin, Chantal Combredet, Christiane Moog, Gérard Pierron, Thierry Heidmann, Frédéric Tangy, Leslie Gosse, Sylvie Souquere, Claude Ruffié, Caroline Petitdemange, Physiologie et physiopathologie des rétrovirus endogènes et infectieux (RETRO-ENDO), Institut Gustave Roussy (IGR)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), VIROxIS [Villejuif], Institut Gustave Roussy (IGR), Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Génomique virale et vaccination, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Inflammation, microbiome, immunosurveillance (MI2), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), This work was supported by the ANR LENTIxIS project (ANR-11-RPIB-0010 to UMR9196 and VIROxIS), the ANR Programme Investissements d’Avenir (PIA) (ANR-11-INBS-0008) funding the IDMIT infrastructure (Fontenay-aux-Roses, France), and the ANR-10-EQPX-02-01 funding the FlowCyTech facility of IDMIT., ANR-11-RPIB-0010,LENTIxIS,Mise au point d'antigènes optimisés pour le développement de vaccins contre les lentivirus(2011), ANR-11-INBS-0008,IDMIT,Infrastructure nationale pour la modélisation des maladies infectieuses humaines(2011), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), combredet, chantal, RECHERCHES PARTENARIALES ET INNOVATION BIOMEDICALE - Mise au point d'antigènes optimisés pour le développement de vaccins contre les lentivirus - - LENTIxIS2011 - ANR-11-RPIB-0010 - RPIB - VALID, and Infrastructures - Infrastructure nationale pour la modélisation des maladies infectieuses humaines - - IDMIT2011 - ANR-11-INBS-0008 - INBS - VALID

Subjects
Live attenuated vaccines, viruses, [SDV]Life Sciences [q-bio], Immunology, Viremia, Virus, Article, Viral vector, Measles virus, 03 medical and health sciences, 0302 clinical medicine, [SDV.IMM.VAC] Life Sciences [q-bio]/Immunology/Vaccinology, Immunity, medicine, Pharmacology (medical), 030212 general & internal medicine, RC254-282, 030304 developmental biology, Pharmacology, 0303 health sciences, biology, Immunogenicity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, virus diseases, RC581-607, biology.organism_classification, medicine.disease, Virology, 3. Good health, Vaccination, [SDV] Life Sciences [q-bio], Infectious Diseases, Preclinical research, Measles vaccine, Immunologic diseases. Allergy, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology
Abstract

Replicative vectors derived from live-attenuated measles virus (MV) carrying additional non-measles vaccine antigens have long demonstrated safety and immunogenicity in humans despite pre-existing immunity to measles. Here, we report the vaccination of cynomolgus macaques with MV replicative vectors expressing simian-human immunodeficiency virus Gag, Env, and Nef antigens (MV-SHIV Wt) either wild type or mutated in the immunosuppressive (IS) domains of Nef and Env antigens (MV-SHIV Mt). We found that the inactivation of Nef and Env IS domains by targeted mutations led to the induction of significantly enhanced post-prime cellular immune responses. After repeated challenges with low doses of SHIV-SF162p3, vaccinees were protected against high viremia, resulting in a 2-Log reduction in peak viremia, accelerated viral clearance, and a decrease -even complete protection for nearly half of the monkeys- in reservoir cell infection. This study demonstrates the potential of a replicative viral vector derived from the safe and widely used measles vaccine in the development of a future human vaccine against HIV-1.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results